|Mr. Peter Lynton Gunzburg B Comm, ASIA||Exec. Chairman & MD||75.28k||N/A||1952|
|Dr. Leearne Maree Hinch BSc., B.V.M.S., M.R.C.V.S., M.B.A.||Chief Exec. Officer||389.4k||N/A||N/A|
|Dr. Irmgard Irminger-Finger||Founder, Exec. Director & Chief Scientific Officer||150k||N/A||N/A|
|Ms. Pauline Anne Collinson||Company Sec.||N/A||N/A||N/A|
BARD1 Life Sciences Limited focuses on developing and commercializing non-invasive diagnostic tests for early detection of cancer in Australia. It is developing BARD1 lung cancer test, a non-invasive blood test for screening and diagnosing lung cancer at early stages of disease progression. The company is also developing BARD1 ovarian cancer test, a non-invasive blood test for early detection of ovarian cancer. It has a collaboration agreement with Institute for Respiratory Health to evaluate a BARD1 cancer vaccine for the prevention and/or treatment of cancer in animal models; and Thermo Fisher Scientific to develop multiplex autoantibody assay. BARD1 Life Sciences Limited is headquartered in Nedlands, Australia.
BARD1 Life Sciences Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.